Ultragenyx Pharmaceutical RARE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$608.92M-5.9% | -$574.92M+0.8% | -$579.57M-8.8% | -$532.67M+3.0% | -$549.32M+3.5% | ||
| $34M-2.9% | $35M-2.1% | $35.75M-0.4% | $35.9M-0.7% | $36.16M+0.4% | ||
| -$497M-6.7% | -$466M-4.6% | -$445.49M-5.8% | -$421.06M-8.2% | -$389.27M+6.0% | ||
| $6M0.0% | $6M+14.8% | $5.23M-6.1% | $5.56M+16.2% | $4.79M-31.6% | ||
| —— | —— | —— | —— | —— | ||
| $50M-80.2% | $252M— | —— | —— | —— | ||
| -$503M-6.6% | -$472M-4.7% | -$450.71M-5.6% | -$426.62M-8.3% | -$394.06M+6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ultragenyx Pharmaceutical's cash flow data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.